The standard of care for patients with resected stage I to stage III pancreatic ductal adenocarcinoma (PDAC) is adjuvant gemcitabine-based chemotherapy. The role of adjuvant treatment in patients with subcentimeter, stage IA PDAC is unknown. The current study evaluated the effect of adjuvant treatment on survival outcomes among patients with American Joint Committee on Cancer/International Union Against Cancer stage IA (T1N0) resected PDAC using the National Cancer Data Base (NCDB). METHODS: A retrospective review of the NCDB was conducted for patients diagnosed with T1 (tumor limited to the pancreas and measuring ≤2 cm in greatest dimension), lymph node-negative (N0), resected PDAC between 2004 and 2013. Patient demographics, histology, adjuvant treatment, and survival trends were examined. Kaplan-Meier analysis and log-rank tests were performed to determine the unadjusted association between overall survival (OS), tumor size, and treatment. RESULTS: A total of 876 patients met the inclusion criteria. The patients had a mean age of 66.2 years (range, 32-90 years); approximately 83.3% were white (730 patients) and 53.1% were female (465 patients). Approximately 45.9% of the patients had moderately differentiated tumor histology (402 patients); 70.0% (613 patients) had tumors measuring 1 to 2 cm (T1c) and 30.0% (263 patients) had tumors measuring <1 cm (T1a/T1b). Approximately 94.2% of patients had negative surgical margins (815 patients) and 46.9% (410 patients) received adjuvant therapy. The median OS was significantly different for patients who received adjuvant therapy compared with patients who did not (70.7 months vs 46.9 months; P=.0001). For patients with tumors measuring <1 cm, survival was not found to be significantly different between patients who received adjuvant treatment compared with those who did not (not reached vs 85.3 months; P=.54). In the multivariable analysis, none of the covariates (treatment group, Charlson-Deyo Score, age, insurance, and facility status) demonstrated significant differences for patients with tumors measuring <1 cm. CONCLUSIONS: The current study is the first to demonstrate no survival benefit for adjuvant therapy in patients with resected subcentimeter PDAC. Cancer 2019;125: 57-67.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest diseases, with a mortality rate approaching its incidence. [1] [2] [3] Due to the difficulty in diagnosing the disease at an early stage and the high potential for metastasis, the majority of patients present with an advanced stage of disease, at which time cure is not possible. 2, 4 Surgery is the only curative approach, and only 15% to 20% of patients are candidates for surgical resection. 2, 4 Approximately 66% to 92% of those patients with resected PDAC develop a disease recurrence within 2 years. [4] [5] [6] The 2017 American Joint Committee on Cancer/International Union Against Cancer staging system defines stage IA disease as a classification of T1 N0. 7 T1 is classified further into T1a (tumors measuring <0.5 cm), T1b (tumors measuring 0.5-1 cm), and T1c (tumors measuring 1-2 cm). 7 A Surveillance, Epidemiology, and End Results database analysis of 8960 patients demonstrated median survival durations for patients with stage IA, stage IB, stage IIA, stage IIB, and stage III disease of 38 months, 24 months, 18 months, 17 months, and 14 months, respectively. 8 In this analysis, approximately 5% of the patients had stage IA (T1N0) disease.
Adjuvant therapy has been an area of research over the past several decades. 9 Adjuvant therapy typically is recommended for patients with PDAC after surgical resection. Two landmark trials, the Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer (CONKO-001) randomized trial. and the
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European Study Group for Pancreatic Cancer (ESPAC-4), established comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. 2, 10 These trials included patients across all locally resected disease stages, but the majority of patients had stage II and stage III disease. In the CONKO-001 trial, patients with resected PDAC were randomized to receive adjuvant single-agent therapy with gemcitabine versus observation. 2 The 5-year overall survival (OS) rates were 20.7% versus 10.4 %, respectively. 2 Of the 179 patients who received gemcitabine, 4% (7 patients) had T1 disease and 82% (146 patients) had T3 PDAC. Of the 175 patients who were randomized to the observation arm, 4% (7 patients) had T1 disease and 83% (146 patients) had T3 PDAC. 2 The results of this trial supported the use of adjuvant single-agent gemcitabine (P=0.01), and defined the standard of care for the adjuvant treatment of patients with resected PDAC.
2,10
The ESPAC-4 trial was a multicenter, open-label, randomized, phase 3 trial that randomized patients to adjuvant gemcitabine and capecitabine combination therapy compared with gemcitabine single-agent adjuvant therapy. 10 The median OS for patients who received adjuvant gemcitabine and capecitabine was 28.0 months compared with 25.5 months for patients treated with gemcitabine alone (P=.032). The median tumor size was 3 cm. Of the 364 patients who received adjuvant gemcitabine and capecitabine, 4% (15 patients) had stage I PDAC and 90% (326 patients) had stage III disease. Among the patients treated with gemcitabine alone, 2% (7 patients) had stage I disease. 10 The ESPAC-4 trial demonstrated that adjuvant treatment with the combination of gemcitabine and capecitabine is superior to single-agent gemcitabine, thereby establishing the current standard of care for the adjuvant treatment of patients with PDAC. 10 The major adjuvant therapy trials, including ESPAC-1, ESPAC-3/ version 1, ESPAC-3/version 2, ESPAC-4, and CONKO-001, with the percentage of patients with stage 1 disease assessed are summarized in Table 1 . 2, [10] [11] [12] [13] Patients with resected stage I PDAC are underrepresented in the PDAC adjuvant trials. This most likely is because of the low prevalence of this disease at the early stage. To our knowledge, there currently are no data supporting the use of adjuvant therapy specifically in patients with resected stage I PDAC. 14 The relatively small sample size of patients with stage IA PDAC in the CONKO-001 and ESPAC-4 trials precludes a meaningful subgroup analysis with which to answer the question of whether adjuvant treatment in patients with stage IA disease would confer a survival benefit. To address this question, the current study used the National Cancer Data Base (NCDB) analysis to evaluate the effect of adjuvant treatment on survival among patients with subcentimeter, resected PDAC. 
Statistical Analysis
Descriptive statistics were generated for each covariate including the mean, median, range, and standard deviation for continuous variables and the frequency and percentage for categorical variables. The endpoint, OS, was defined as the time from diagnosis to the time of death or last known time alive, at which point surviving patients were censored. OS was estimated using the Kaplan-Meier method, and patient groups (those undergoing adjuvant therapy vs surgery alone) were compared using log-rank tests. Univariate Cox proportional hazards models were fit for OS as a function of treatment group (adjuvant treatment vs surgery alone), sex, race (black, white, or other), age, tumor grade, Charlson-Deyo Score (≥1 or 0), surgical margins (positive vs negative), tumor site (pancreatic head, body, or tail), insurance status (private, government insurance, or not insured/unknown), facility type (nonacademic vs academic), lymphovascular invasion (LVI), and tumor size (<0.5 cm, 0.5-1 cm, and 1-2 cm). Multivariable Cox models were considered that included treatment, controlling for the above covariates, with the exception of LVI due to its level of missingness.
In addition, the analysis was stratified by tumor size into subcentimeter versus 1 to 2 cm in size. Model assumptions were checked and verified. The analysis was performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina), and significance was assessed at the .05 level.
RESULTS

Patient Characteristics
A total of 1589 patients with stage IA PDAC underwent surgical resection between 2004 and 2013. Of these, 876 patients met the criteria for study inclusion ( Cancer January 1, 2019 Patients treated with surgical resection alone (ie, without adjuvant treatment) constituted 53.2% of the study population (466 patients). Adjuvant chemotherapy without radiotherapy was used in 27.9% of patients (244 patients), radiotherapy without chemotherapy was used in 1.3% of patients (11 patients), and adjuvant chemoradiation was used in 17.7% of patients (155 patients). patients who did not receive adjuvant therapy (P<.0001). The 12-month, 24-month, and 60-month OS rates were 95.8%, 84.2% and 58.3%, respectively (P<.0001). When stratified for tumor sizes of 1 to 2 cm, the median OS for patients who received adjuvant chemotherapy alone was 78.4 months (vs 30.8 months; P<.0001); the 12-month, 24-month, and 60-month OS rates were 95.5%, 82.1%, and 56.3%, respectively (P<.0001). For patients with subcentimeter tumors, the median OS was not reached for those who received adjuvant chemotherapy without radiotherapy (vs 85.3 months; P=.078); the 12-month, 24-month, and 60-month OS rates were 96.8%, 91.0%, and 64.6%, respectively (P=.078).
For patients with stage IA disease who received any adjuvant radiotherapy, the median OS was 45.6 months (vs. 46.9 months; P=.24). The 12-month, 24-month, and 60-month OS rates were 90.3%, 68.2%, and 47.1%, respectively, versus 79.4%, 67.7%, and 41.2%, respectively for those who did not receive adjuvant radiotherapy (P=.24). When stratified for tumor sizes of 1 to 2 cm, the median OS for patients who received adjuvant radiotherapy was 56.7 months (vs 30.8 months; P=.002). The 12-month, 24-month, and 60-month OS rates were 90.0%, 66.5%, and 48.0%, respectively, which was statistically significant (P=.002). For patients with subcentimeter tumors, the median OS was 40.3 months for patients who Table 5 ).
DISCUSSION
The current standard of care for patients with resected PDAC is adjuvant combination chemotherapy. 10 Previous adjuvant trials (Table 1) have evaluated patients across all stages of PDAC after surgical resection. A minority of the patients in these trials had stage I disease (including T1 and T2 disease). 2, 10 To the best of our knowledge, there are no randomized trials to date evaluating adjuvant treatment specifically for patients with stage IA PDAC because the incidence of this stage of disease at the time of diagnosis is very low. 2, 4 Thus, designing a prospective trial to evaluate adjuvant treatment in patients with stage IA disease would not be feasible. The current study evaluated adjuvant treatment in patients with T1 PDAC using the NCDB. Patients were stratified by tumor size into those with subcentimeter tumors (T1a/T1b) and those with tumors measuring 1 to 2 cm (T1c). Patients with lymph node disease and those who received neoadjuvant treatment were excluded.
The limitations of the current study include the retrospective nature of the analysis, missing data, and miscoding of the disease and treatments. Data analyzed did not include the details of therapy such as the type of radiotherapy, the total dose, the timing and location of the radiotherapy delivered, the dose and type of chemotherapy, the number of cycles, and the toxicities and morbidities of the treatments used. There also is potential selection bias. Some of the patients likely were not prescribed adjuvant treatment due to comorbidities and/or postoperative complications. The study excluded patients who were diagnosed after 2013 due to a lack of survival Cancer January 1, 2019 data and the need for 5-year follow-up. Furthermore, a total of 1589 patients with stage IA disease were identified in the database; 55% were included in the analysis, excluding those patients with missing survival data, a history of neoadjuvant treatment (part of the exclusion criteria), and an unknown treatment sequence. The combination of gemcitabine and capecitabine was less likely to be used given the time frame of this analysis, which might have affected the outcomes. 10 This may affect the extent to which comparisons can be adjusted.
In the CONKO-001 trial, serious treatment-related adverse effects of adjuvant therapy were reported in approximately 14% of patients. 2 Of the 359 patients in the ESPAC-4 trial who received adjuvant combination therapy with gemcitabine and capecitabine, 63% had grade 3 and grade 4 toxicities, which included neutropenia, leukopenia, hand-foot syndrome, fatigue, diarrhea, and anemia, among others. 10 The cost for 1 month of the combination therapy of gemcitabine and capecitabine is approximately US$25,625. 15 The results of the Cancer January 1, 2019 current study demonstrated that adjuvant therapy does not confer an OS benefit for patients with resected, stage IA, subcentimeter T1a/T1b PDAC. Thus, repercussions of the cost of therapy and the side effects of treatment may outweigh the benefits in this group of patients with PDAC. The role of radiotherapy in the adjuvant setting for patients with PDAC remains controversial. 16 The ESPAC-1 trial compared patients with resected PDAC who received adjuvant concurrent chemotherapy and radiotherapy compared with chemotherapy alone, chemotherapy followed by chemoradiation, and observation only. 11, 16 The study demonstrated an OS benefit for adjuvant chemotherapy compared with concurrent chemoradiation (20.1 months vs 15.9 months; P=.009), and demonstrated that concurrent chemoradiation has a deleterious effect on survival, with shorter rates of recurrence-free survival (10.7 months vs 15.2 months; P=.04) and higher rates of adverse events (6% vs 4%) when compared with adjuvant chemotherapy. 11, 16 In the current study, among patients with resected, subcentimeter (T1a/ T1b) stage IA PDAC, radiotherapy appeared to have a nonsignificant trend toward shorter survival compared with patients who were treated with no radiotherapy.
IPMNs are precancerous lesions with a risk of developing into invasive carcinoma that approaches 30%. To the best of our knowledge, there are no radiographic or clinical characteristics that reliably predict malignancy in patients with IPMNs. 23 It was expected that the majority of patients with subcentimeter PDACs would have a preoperative diagnosis of IPMN. In this analysis, only 9% of all patients with stage I PDAC had a coexisting diagnosis of IPMN; 16% of patients with stage IA PDAC disease had IPMN. Contrary to the expectations, this number is relatively low because subcentimeter PDACs are expected to be incidental after surgical resection for IPMN. The number of observations in the original data set was 263. The number of observations used was 252. b Backward selection with an α level of removal of .1 was used. No variables were removed from the model.
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The current study is the first to evaluate adjuvant therapy in a small subgroup of patients with stage IA, resected PDAC, which is underrepresented in prospective adjuvant trials. Chemotherapy and radiotherapy both have significant cost and adverse effects. Based on this analysis, adjuvant therapy for all patients with stage I, resected pancreatic cancer demonstrated benefit; patients with subcentimeter (T1a/T1b) tumors are unlikely to benefit from adjuvant therapy. This likely could be related to the number of patients involved in the current analysis and the limitations of using retrospective data. Evaluation of the effects of adjuvant therapy in this group of patients using prospective randomized trials was not feasible given the very low incidence of this stage of disease at the time of diagnosis. 2, 4 Based on these results, a review of the standard of care for patients with resected PDAC may be warranted, wherein adjuvant therapy is not recommended for patients with resected T1a/T1b PDAC with negative surgical resection margins. 
FUNDING SUPPORT
